Heidelberg Pharma AG Revises Financial Guidance for 2025

Heidelberg Pharma AG has announced an update to its financial guidance for 2025, citing strategic focus and cost-saving measures. The biotech company, notable for its development of Antibody Drug Conjugates (ADCs), projects sales and other income between EUR 7.5 million and EUR 9 million, a decrease from the previous range of EUR 9 million to EUR 11 million. Operating expenses are also adjusted to EUR 36 million to EUR 40 million, down from the prior forecast of EUR 40 million to EUR 45 million.

The expected operating result (EBIT) is now in the range of EUR -28.5 million to EUR -31 million, improved from initial expectations. Heidelberg Pharma is reviewing both long-term and short-term assets for impairment, which could affect the operating result further. The company foresees cash requirements of EUR 14 million to EUR 17 million for 2025, with financing secured until mid-2026.